Adamson D L, Webb C M, Collins P
Cardiac Medicine, Imperial College School of Medicine at the National Heart & Lung Institute, and Royal Brompton Hospital, London, United Kingdom.
Menopause. 2001 Jul-Aug;8(4):233-8. doi: 10.1097/00042192-200107000-00003.
The cardiac syndrome X is described as the triad of angina pectoris, a positive exercise test for myocardial ischemia, and angiographically smooth coronary arteries. Although syndrome X does not result in an increased risk of cardiovascular mortality, the symptoms are often troublesome and unresponsive to conventional antianginal therapy. The majority of patients are postmenopausal, and estrogen therapy can alleviate anginal symptoms. We investigated the effect of esterified estrogens combined with methyltestosterone (Estratest) on quality of life in postmenopausal women with syndrome X.
Patients were withdrawn from antianginal therapy. Sublingual nitrates were allowed for treatment of anginal episodes. Patients underwent treadmill testing, and quality of life was assessed by using the Short Form-36 and Cardiac Health Profile questionnaires after the women had received 8 weeks of Estratest or identical placebo in a randomized, double-blind, cross-over study.
Nineteen patients were randomized, and 16 patients completed the protocol. Plasma 17beta-estradiol concentrations were significantly increased by Estratest; however, total testosterone levels were not. The "emotional" score of the Cardiac Health Profile questionnaire was significantly improved after Estratest use compared with placebo (p = 0.03); however, there was no significant change in the Short Form-36 questionnaire for any variable. Estratest significantly increased systolic blood pressure and rate pressure product at rest but had no effect on exercise parameters. Time to onset of chest pain during exercise was also unaffected.
We have demonstrated a beneficial effect of Estratest on emotional well-being in postmenopausal women with cardiological syndrome X. There was no significant treatment effect on exercise parameters, including time to onset of chest pain.
心脏X综合征被描述为具有以下三联征:心绞痛、心肌缺血运动试验阳性以及冠状动脉造影显示血管光滑。尽管X综合征不会增加心血管疾病死亡风险,但症状往往令人困扰且对传统抗心绞痛治疗无反应。大多数患者为绝经后女性,雌激素治疗可缓解心绞痛症状。我们研究了酯化雌激素联合甲基睾酮(复方雌激素)对绝经后心脏X综合征女性生活质量的影响。
患者停用抗心绞痛治疗。允许使用舌下硝酸酯类药物治疗心绞痛发作。患者接受平板运动试验,并在随机、双盲、交叉研究中,在女性接受8周复方雌激素或相同安慰剂治疗后,使用简短健康调查问卷(SF-36)和心脏健康状况调查问卷评估生活质量。
19名患者被随机分组,16名患者完成了研究方案。复方雌激素使血浆17β-雌二醇浓度显著升高;然而,总睾酮水平未升高。与安慰剂相比,使用复方雌激素后心脏健康状况调查问卷的“情绪”得分显著改善(p = 0.03);然而,简短健康调查问卷的任何变量均无显著变化。复方雌激素显著增加静息时的收缩压和心率血压乘积,但对运动参数无影响。运动期间胸痛发作时间也未受影响。
我们已证明复方雌激素对绝经后心脏X综合征女性的情绪健康有有益影响。对运动参数,包括胸痛发作时间,没有显著的治疗效果。